Complement plays a minimal role in Sm-p80-mediated protection against Schistosoma mansoni

References

• Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368:1106 - 18; http://dx.doi.org/10.1016/S0140-6736(06)69440-3; PMID: 16997665
   PubMed Web of Science ®Google Scholar
• Gryseels B. Schistosomiasis. Infect Dis Clin North Am 2012; 26:383 - 97; http://dx.doi.org/10.1016/j.idc.2012.03.004; PMID: 22632645
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl Trop Dis 2009; 3:e485; http://dx.doi.org/10.1371/journal.pntd.0000485; PMID: 19787054
   PubMed Web of Science ®Google Scholar
• Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuenté LA, Garba A, Mohammed KA, Schur N, Person B, Colley DG, et al. Time to set the agenda for schistosomiasis elimination. Acta Trop 2013; 128:423 - 40; http://dx.doi.org/10.1016/j.actatropica.2012.04.013; PMID: 22580511
   PubMed Web of Science ®Google Scholar
• Ross AG, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, McManus DP. Schistosomiasis. N Engl J Med 2002; 346:1212 - 20; http://dx.doi.org/10.1056/NEJMra012396; PMID: 11961151
   PubMed Web of Science ®Google Scholar
• King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010; 113:95 - 104; http://dx.doi.org/10.1016/j.actatropica.2009.11.012; PMID: 19962954
   PubMed Web of Science ®Google Scholar
• King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis 2011; 5:e1321; http://dx.doi.org/10.1371/journal.pntd.0001321; PMID: 21949893
   PubMedGoogle Scholar
• Parker M, Allen T. Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. Health Res Policy Syst 2011; 9:3; http://dx.doi.org/10.1186/1478-4505-9-3; PMID: 21211001
   PubMedGoogle Scholar
• Prichard RK, Basáñez MG, Boatin BA, McCarthy JS, García HH, Yang GJ, Sripa B, Lustigman S. A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl Trop Dis 2012; 6:e1549; http://dx.doi.org/10.1371/journal.pntd.0001549; PMID: 22545163
   PubMed Web of Science ®Google Scholar
• Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?. Trends Parasitol 2005; 21:112 - 7; http://dx.doi.org/10.1016/j.pt.2005.01.001; PMID: 15734657
   PubMed Web of Science ®Google Scholar
• Bergquist R, Al-Sherbiny M, Barakat R, Olds R. Blueprint for schistosomiasis vaccine development. Acta Trop 2002; 82:183 - 92; http://dx.doi.org/10.1016/S0001-706X(02)00048-7; PMID: 12020891
   PubMed Web of Science ®Google Scholar
• Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008; 2:e244; http://dx.doi.org/10.1371/journal.pntd.0000244; PMID: 18575619
   PubMed Web of Science ®Google Scholar
• Karcz SR, Podesta RB, Siddiqui AA, Dekaban GA, Strejan GH, Clarke MW. Molecular cloning and sequence analysis of a calcium-activated neutral protease (calpain) from Schistosoma mansoni. Mol Biochem Parasitol 1991; 49:333 - 6; http://dx.doi.org/10.1016/0166-6851(91)90078-K; PMID: 1775175
   PubMed Web of Science ®Google Scholar
• Andresen K, Tom TD, Strand M. Characterization of cDNA clones encoding a novel calcium-activated neutral proteinase from Schistosoma mansoni. J Biol Chem 1991; 266:15085 - 90; PMID: 1869543
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Zhou Y, Podesta RB, Karcz SR, Tognon CE, Strejan GH, Dekaban GA, Clarke MW. Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta 1993; 1181:37 - 44; http://dx.doi.org/10.1016/0925-4439(93)90087-H; PMID: 8457603
   PubMed Web of Science ®Google Scholar
• Silva EE, Clarke MW, Podesta RB. Characterization of a C3 receptor on the envelope of Schistosoma mansoni. J Immunol 1993; 151:7057 - 66; PMID: 8258710
   PubMed Web of Science ®Google Scholar
• Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, Le L, Siddiqui AA. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009; 105:1767 - 77; http://dx.doi.org/10.1007/s00436-009-1646-z; PMID: 19809833
   PubMed Web of Science ®Google Scholar
• Ahmad G, Torben W, Zhang W, Wyatt M, Siddiqui AA. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol 2009; 31:156 - 61; http://dx.doi.org/10.1111/j.1365-3024.2008.01091.x; PMID: 19222788
   PubMed Web of Science ®Google Scholar
• Ahmad G, Zhang W, Torben W, Damian RT, Wolf RF, White GL, Chavez-Suarez M, Kennedy RC, Siddiqui AA. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009; 27:2830 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.02.096; PMID: 19366570
   PubMed Web of Science ®Google Scholar
• Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis 2010; 14:e781 - 7; http://dx.doi.org/10.1016/j.ijid.2010.02.2266; PMID: 20630783
   PubMed Web of Science ®Google Scholar
• Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF, White GL, Carey DW, Mwinzi PN, Ganley-Leal L, et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis 2011; 204:1437 - 49; http://dx.doi.org/10.1093/infdis/jir545; PMID: 21921206
   PubMed Web of Science ®Google Scholar
• El Ridi R, Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine 2009; 27:666 - 73; http://dx.doi.org/10.1016/j.vaccine.2008.11.039; PMID: 19056448
   PubMed Web of Science ®Google Scholar
• El Ridi R, Tallima H, Mahana N, Dalton JP. Innate immunogenicity and in vitro protective potential of Schistosoma mansoni lung schistosomula excretory--secretory candidate vaccine antigens. Microbes Infect 2010; 12:700 - 9; http://dx.doi.org/10.1016/j.micinf.2010.04.012; PMID: 20452455
   PubMed Web of Science ®Google Scholar
• Hota-Mitchell S, Siddiqui AA, Dekaban GA, Smith J, Tognon C, Podesta RB. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine 1997; 15:1631 - 40; http://dx.doi.org/10.1016/S0264-410X(97)00081-9; PMID: 9364694
   PubMed Web of Science ®Google Scholar
• Hota-Mitchell S, Clarke MW, Podesta RB, Dekaban GA. Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model. Vaccine 1999; 17:1338 - 54; http://dx.doi.org/10.1016/S0264-410X(98)00391-0; PMID: 10195769
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, Lloyd JD, Pompa J, Villalovos RM, Paz M. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 2003; 21:2882 - 9; http://dx.doi.org/10.1016/S0264-410X(03)00159-2; PMID: 12798631
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, Lloyd JD, Paz M, Villalovos RM, Pompa J. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect Immun 2003; 71:3844 - 51; http://dx.doi.org/10.1128/IAI.71.7.3844-3851.2003; PMID: 12819068
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Pinkston JR, Quinlin ML, Kavikondala V, Rewers-Felkins KA, Phillips T, Pompa J. Characterization of protective immunity induced against Schistosoma mansoni via DNA priming with the large subunit of calpain (Sm-p80) in the presence of genetic adjuvants. Parasite 2005; 12:3 - 8; http://dx.doi.org/10.1051/parasite/2005121003; PMID: 15828575
   PubMed Web of Science ®Google Scholar
• Zhang W, Ahmad G, Torben W, Noor Z, Le L, Damian RT, Wolf RF, White GL, Chavez-Suarez M, Podesta RB, et al. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis 2010; 201:1105 - 12; http://dx.doi.org/10.1086/651147; PMID: 20187746
   PubMed Web of Science ®Google Scholar
• Zhang W, Ahmad G, Torben W, Siddiqui AA. Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse. Parasite Immunol 2010; 32:252 - 8; http://dx.doi.org/10.1111/j.1365-3024.2009.01181.x; PMID: 20398225
   PubMed Web of Science ®Google Scholar
• Zhang W, Ahmad G, Torben W, Siddiqui AA. Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). Acta Trop 2011; 118:142 - 51; http://dx.doi.org/10.1016/j.actatropica.2011.01.010; PMID: 21334302
   PubMed Web of Science ®Google Scholar
• Ohta N, Kumagai T, Maruyama H, Yoshida A, He Y, Zhang R. Research on calpain of Schistosoma japonicum as a vaccine candidate. Parasitol Int 2004; 53:175 - 81; http://dx.doi.org/10.1016/j.parint.2004.01.007; PMID: 15081949
   PubMed Web of Science ®Google Scholar
• Zhang R, Yoshida A, Kumagai T, Kawaguchi H, Maruyama H, Suzuki T, Itoh M, El-Malky M, Ohta N. Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect Immun 2001; 69:386 - 91; http://dx.doi.org/10.1128/IAI.69.1.386-391.2001; PMID: 11119528
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Siddiqui BA, Ganley-Leal L. Schistosomiasis vaccines. Hum Vaccin 2011; 7:1192 - 7; http://dx.doi.org/10.4161/hv.7.11.17017; PMID: 22048120
   PubMed Web of Science ®Google Scholar
• Kumagai T, Maruyama H, Hato M, Ohmae H, Osada Y, Kanazawa T, Ohta N. Schistosoma japonicum: localization of calpain in the penetration glands and secretions of cercariae. Exp Parasitol 2005; 109:53 - 7; http://dx.doi.org/10.1016/j.exppara.2004.11.001; PMID: 15639140
   PubMed Web of Science ®Google Scholar
• Mourão MM, Dinguirard N, Franco GR, Yoshino TP. Phenotypic screen of early-developing larvae of the blood fluke, schistosoma mansoni, using RNA interference. PLoS Negl Trop Dis 2009; 3:e502; http://dx.doi.org/10.1371/journal.pntd.0000502; PMID: 19668375
   PubMedGoogle Scholar
• Braschi S, Wilson RA. Proteins exposed at the adult schistosome surface revealed by biotinylation. Mol Cell Proteomics 2006; 5:347 - 56; http://dx.doi.org/10.1074/mcp.M500287-MCP200; PMID: 16269422
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Pinkston JR, Quinlin ML, Saeed Q, White GL, Shearer MH, Kennedy RC. Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon. Vaccine 2005; 23:1451 - 6; http://dx.doi.org/10.1016/j.vaccine.2004.09.018; PMID: 15670880
   PubMed Web of Science ®Google Scholar
• Torben W, Ahmad G, Zhang W, Siddiqui AA. Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models. Vaccine 2011; 29:2262 - 71; http://dx.doi.org/10.1016/j.vaccine.2011.01.040; PMID: 21277404
   PubMed Web of Science ®Google Scholar
• Torben W, Ahmad G, Zhang W, Nash S, Le L, Karmakar S, Siddiqui AA. Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni. Vaccine 2012; 30:6753 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.09.026; PMID: 23000221
   PubMed Web of Science ®Google Scholar
• Arnon R, Tarrab-Hazdai R, Steward M. A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization. Immunology 2000; 101:555 - 62; http://dx.doi.org/10.1046/j.1365-2567.2000.00139.x; PMID: 11122460
   PubMed Web of Science ®Google Scholar
• Deng J, Gold D, LoVerde PT, Fishelson Z. Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin. Infect Immun 2003; 71:6402 - 10; http://dx.doi.org/10.1128/IAI.71.11.6402-6410.2003; PMID: 14573661
   PubMed Web of Science ®Google Scholar
• De Brito T, Hoshino-Shimizu S, da Silva LC, Kanamura H, Costa CM, Pinto PS. Immunopathology of experimental schistosome (S. Mansoni) egg granulomas in mice--possible defence mechanisms mediated by local immune complexes. J Pathol 1983; 140:17 - 28; http://dx.doi.org/10.1002/path.1711400104; PMID: 6343568
   PubMed Web of Science ®Google Scholar
• La Flamme AC, MacDonald AS, Huxtable CR, Carroll M, Pearce EJ. Lack of C3 affects Th2 response development and the sequelae of chemotherapy in schistosomiasis. J Immunol 2003; 170:470 - 6; PMID: 12496433
   PubMed Web of Science ®Google Scholar
• Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, Davis HL, Eisenberg RJ, Cohen GH, Isaacs SN. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 2010; 28:6627 - 36; http://dx.doi.org/10.1016/j.vaccine.2010.07.030; PMID: 20659519
   PubMed Web of Science ®Google Scholar
• Böttger EC, Metzger S, Bitter-Suermann D, Stevenson G, Kleindienst S, Burger R. Impaired humoral immune response in complement C3-deficient guinea pigs: absence of secondary antibody response. Eur J Immunol 1986; 16:1231 - 5; http://dx.doi.org/10.1002/eji.1830161008; PMID: 2945728
   PubMed Web of Science ®Google Scholar
• Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, Han S, Kelsoe G, Howard RG, Rothstein TL, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996; 157:549 - 56; PMID: 8752901
   PubMed Web of Science ®Google Scholar
• Purwar R, Bäumer W, Niebuhr M, Tschernig T, Kietzmann M, Werfel T. A protective role of complement component 3 in T cell-mediated skin inflammation. Exp Dermatol 2011; 20:709 - 14; http://dx.doi.org/10.1111/j.1600-0625.2011.01295.x; PMID: 21569105
   PubMed Web of Science ®Google Scholar